Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?
Merck shares rose 12.6% to a record $152.20 on August 19 after Phase 3 INTerpath-001 showed intismeran plus Keytruda significantly improved recurrence-free survival and distant-metastasis-free survival versus Keytruda alone, with no new safety concerns.
Aug 25, 2026 ·
Yahoo Finance
















